Compare Illumina, Inc. (ILMN) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Prospect Capital Corporation — how do they compare? Illumina, Inc. trades at $265.87 (market cap $39.95B), while Prospect Capital Corporation trades at $1.83 (market cap $974.22M). The key difference: Illumina, Inc. is far larger — about 41× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Prospect Capital Corporation for 78 Days on average.
| ILMN | PSEC | |
|---|---|---|
Market Cap | $39.95B | $974.22M |
Volume | 3,169,503 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $293.69 | $3.05 |
52-Week Low | $91.00 | $1.82 |
Typical Hold Time | 83 Days | 78 Days |
Enterprise Value | $41.31B | $2.73B |
Dividend Yield | — | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
PSEC trades at $1.84, up 0.55% with bearish technical signals despite recent earnings beats. The company shows inconsistent revenue trends with 2025 revenue at -$407M and net income of -$470M, though 2026 projections indicate recovery. Dividend payments continue at $0.04 monthly, while analyst sentiment remains mixed with 25% buy ratings amid concerns about NAV erosion and portfolio contraction.
PSEC presents high risk with volatile financial performance and bearish technical indicators. The 18%+ dividend yield appears unsustainable given negative cash flow and declining portfolio value. While current price represents a significant discount to book value, ongoing NAV erosion and mixed analyst consensus suggest cautious approach for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
